Post-transplant biliary complications using liver grafts from deceased donors older than 70 years: Retrospective case-control study

Table 2 Pre-liver transplantation recipient characteristics

Variables	BC (n = 21)	Non-BC (n = 229)	P value
Age (yr)	59 ± 10	59 ± 12	0.767
Sex (female)	3 (14.3)	53 (23.1)	0.264
LT indications, n (%)
Alcohol	11 (52.4)	97 (42.4)	0.705
HCV	7 (33.3)	80 (34.9)	0.883
HBV	0	27 (11.8)	0.081
Biliary related	1 (4.8)	5 (2.2)	0.413
Other	2 (9.5)	20 (8.7)	0.244
HCC, n (%)	7 (43.8)	70 (30.6)	0.793
Pre-LT TACE, n (%)	3 (42.9)	31 (44.3)	0.631
MELD	11 ± 7	13 ± 7	0.334
MELD-Na	11 ± 8	13 ± 8	0.189
D-MELD	810 ± 526	996 ± 510	0.360
UNOS status, n (%)
Home	19 (90.5)	212 (93.4)	0.343
Hospital	1 (4.8)	13 (5.7)
ICU	1 (4.8)	2 (5.2)
Medical history, n (%)
Hypertension	6 (28.6)	46 (20.1)	0.254
Diabetes	6 (28.6)	44 (19.2)	0.223
Pre-LT major abdominal operations	5 (23.8)	23 (10)	0.069
Laboratory values, n (%)
Serum glucose (mg/dL)	130 ± 56	128 ± 63	0.801
Serum creatinine (mg/dL)	1.1 ± 0.8	1 ± 0.6	0.823
Serum albumin (g/dL)	3.6 ± 0.6	3.4 ± 0.6	0.203
AST (IU/L)	53 ± 42	54 ± 56	0.836
ALT (IU/L)	33 (33)	33 ± 36	0.955
GGT (IU/L)	57 ± 129	61 ± 70	0.645
Total bilirubin (mg/dL)	1.1 ± 0.9	1.7 ±2	0.036
Leukocytes/mm3	4483 ± 2819	5356 ± 3110	0.063
Hemoglobin (g/100 mL)	12.6 ± 4.4)	12.3 ± 3.1	0.986
Platelets × 103/mm3	100.7 ± 75.6	94.2 ± 50.2	0.496
Prothrombin rate (%)	70.6 ± 22.2	65 ± 18.3	0.030
aPTT (s)	34.9 ± 5.3	36.4 ± 8.1	0.272

BC: Biliary complications; ALT: Alanine aminotransferase; aPTT: Activated partial thromboplastin time; AST: Aspartate aminotransferase; D-MELD: Donor model for end-stage liver disease; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; ICU: Intensive care unit; LT: Liver transplantation; MELD: Model for end-stage liver disease; TACE: Transarterial chemoembolization; UNOS: United Network for Organ Sharing.